# Weight Loss Surgeries Decline as GLP-1 Use Skyrockets. Why This Matters
Bariatric surgeries are losing ground to injectable medications. Data shows a sharp drop in weight loss surgeries over the past two years as GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become increasingly accessible.
This shift reflects a fundamental change in how people approach obesity treatment. Surgeries like gastric bypass and gastric banding require invasive procedures, extended recovery times, and permanent anatomical changes. GLP-1 medications offer an oral or injectable alternative that produces weight loss without surgery. Patients lose an average of 15 to 22 percent of body weight with these drugs, comparable to many surgical outcomes.
The numbers tell the story. Surgeons report patient volumes dropping by 20 to 40 percent at some centers. Insurance companies are seeing fewer prior authorization requests for bariatric procedures. Meanwhile, GLP-1 prescriptions have surged into the millions annually across the United States.
The change raises practical questions. Surgery remains valuable for people who don't respond adequately to medication or who need rapid weight loss for health reasons. Some patients benefit from the structural limitation that surgery provides, while others do better with the behavioral flexibility of injectable treatments.
Cost considerations shift the equation too. GLP-1 medications run roughly $900 to $1,300 monthly without insurance, making them expensive but potentially cheaper than surgery over time when accounting for hospitalization, recovery leave, and potential complications like nutritional deficiencies or internal hernias.
Experts caution against viewing this as a simple replacement. Bariatric surgery remains the most effective weight loss intervention for severe obesity, particularly when complications develop. Surgery also